Table 1.

Baseline characteristics of patients with eosinophilia during anti-tuberculosis treatment

Variable	All (n = 262)
Age, yr	60 (45–73)
Male sex	175 (66.8)
Type of TB
Pulmonary TB	162 (61.8)
Extrapulmonary TB	100 (38.2)
Adverse reactions
GI disorder	118 (45.0)
Abnormal liver function	32 (12.2)
Abnormal renal function	10 (3.8)
CADRs	161 (61.5)
Pruritus only	76 (47.2)
Skin rash	77 (47.8)
DRESS	7 (4.4)
SJS/TEN	1 (0.6)
Fever	15 (5.7)
History of previous anti-TB treatment
New treatment	238 (90.8)
Retreatment	24 (9.2)
Peripheral blood eosinophilia
Eosinophil count before start of anti-TB treatment, /mL	110 (70–200)
Eosinophil percentage before start of anti-TB treatment, % of total white blood cell count	1.9 (0.9–3.1)
Initial eosinophil count/mL	400 (300–500)
Initial eosinophil percentage, % of total white blood cell count	6.2 (5.4–7.7)
Peak eosinophil count/mL	465 (300–650)
Peak eosinophil percentage, % of total white blood cell count	7.7 (6.0–10.7)

Values are presented as median (interquartile range) or number (%).

TB, tuberculosis; GI, gastrointestinal; CADR, cutaneous adverse drug reaction; DRESS, drug reaction with eosinophilia and systemic symptom; SJS/TEN, Stevens-Johnson syndrome/toxic epidermal necrolysis.